

Research Article

Four *Ab Initio* Whole Cell Kinetic Models of *Bacillus subtilis* 168 (bsuLL25) 6051-HGW (bshSM25), N33 (bsuN33SS25), FUA2231 (bsuGR25)

Sriinithi Maiyappan^{1,2}, Shannon SY Sim^{1,2}, Geeta Ramesh^{1,2}, Lingxin Low^{1,2}, Manjitha L Matarage^{1,2}, Maurice HT Ling^{1,2,3*}

¹School of Life Sciences, Management Development Institute of Singapore, Singapore

²Department of Applied Sciences, Northumbria University, United Kingdom

³HOHY PTE LTD, Singapore

*Correspondence author: Maurice HT Ling, School of Life Sciences, Management Development Institute of Singapore, Singapore; Department of Applied Sciences, Northumbria University, United Kingdom and HOHY PTE LTD, Singapore; Email: mauriceling@acm.org

Citation: Maiyappan S, et al. Four *Ab Initio* Whole Cell Kinetic Models of *Bacillus subtilis* 168 (bsuLL25) 6051-HGW (bshSM25), N33 (bsuN33SS25), FUA2231 (bsuGR25). *J Clin Immunol Microbiol.* 2025;6(2):1-6.

<http://dx.doi.org/10.46889/JCIM.2025.6206>

Received Date: 22-06-2025

Accepted Date: 08-07-2025

Published Date: 15-07-2025



Copyright: © 2025 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CCBY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract

Bacillus subtilis has been used in synthetic biology and metabolic engineering due to its generally recognized as safe status, its tolerance to harsh conditions and high protein expression and secretion abilities. Whole cell kinetic models are useful for in silico screening and evaluation of engineering approaches prior to experimental manipulations. However, there is no whole cell KM of *B. subtilis* to date. In this study, we present four whole cell KMs of *B. subtilis* - one KM for each strain of *B. subtilis*; namely, 168, 6051-HGW, N33 and FUA2231; as models bsuLL25, bshSM25, bsuN33SS25 and bsuGR25 respectively. Each of these four KMs contain between 1300 and 1565 reactions, catalyzes by between 571 and 679 enzyme types; which uses between 1053 and 1681 metabolites. These models can be a baseline models for incorporating other cellular and growth processes or as a system to examine cellular resource allocations necessary for engineering.

Keywords: *Bacillus subtilis*; Gram-Negative Microorganism; *E. coli*

Introduction

While *Escherichia coli* is a model organism of Gram-negative microorganism [1], *Bacillus subtilis* is a model organism of Gram-positive microorganism [2]. Similar to *E. coli*, *B. subtilis* is a common cell factory for many applications [3-5] including probiotics [6] and space microbiology [7] such as potential survivability in Mars [8]. Hence, *B. subtilis* is often a candidate for applications in harsh environments [9]. Furthermore, *B. subtilis* is a Generally Recognized As Safe (GRAS) organism [10] as it has been used in food fermentation [11] and is employed in synthetic biology and metabolic engineering due to its protein expression and

secretion abilities [12].

Mathematical modelling is an important tool in metabolic engineering [13] as it can predict biological phenotypes under metabolic perturbations, which can be used to guide engineering approaches [14]. Genome-Scale Models (GSMs, also known as constraint-based models) and Kinetic Models (KMs) are the two main modelling approaches [15]. Transgenes can be added into KMs easier than GSMs [16]. Furthermore, KMs can predict both rates and yield of metabolites [17] while GSMs are primarily for rates. This makes KMs a more suitable tool for in silico screening and evaluation of engineering approaches prior to experimental manipulations compared to GSMs.

Although there are GSMs of *B. subtilis*, there is no whole cell KM of *B. subtilis* to date. Hence, this study aims to construct whole cell KMs of *B. subtilis* [18-20]. Here, we present four whole cell KM of *B. subtilis* based on four strains of *B. subtilis*; namely, 168, 6051-HGW, N33, FUA2231.

Materials and Methods

Model Development

The reactomes of *B. subtilis* 168, 6051-HGW, N33, FUA2231 were identified from its genomes; Accession numbers NC_000964.3 [21, 22], NC_020507.1 [23], NZ_CP163458.1 and NZ_CP154918.1, respectively; via identification of enzymatic genes using the process previously described [24-27]. The end result was a list of enzymes, a list of substrates and products of each enzymatic reactions and a list of metabolites deduced from the substrates and products. The production of each enzyme was modelled as the production of mRNA and peptide as previously described [16, 27]. Briefly, the production of each enzyme was modelled as a pair of ODEs [28] - an ODE for transcription and an ODE for translation. Based on BioNumbers 106199 [29] and 111676 [30], *E. coli* cell is has about 750 active units of RNA polymerase capable of polymerizing 22 ribonucleotides per second (BioNumbers 104109) [31]. At 339.5 Daltons per ribonucleotide, the total mRNA synthesis rate at 5600 kDa per second or 9.3×10^{-18} grams per second. An *E. coli* cell is about 0.7 cubic micrometres [32] or 7×10^{-16} litres with 4225 protein-coding genes (BioNumbers 105443) [33], the total mRNA synthesis rate is estimated at 2.92 μM per protein-coding genes per second. The average lifespan of mRNA transcripts is 1.79 minutes (BioNumbers 107666) [34] or 107.56 seconds; therefore, 0.93% degraded per second. Therefore, the rate law for mRNA concentration can be written as $d[\text{mRNA}]/dt = (0.00292 - 0.0093[\text{mRNA}]) \text{ mM per second}$. Similarly, the median protein synthesis in mammalian cell culture is 1000 peptides per mRNA transcript per hour (BioNumbers 106382) [35], which equates to 0.278 peptides per mRNA transcripts per second; and the average protein degradation rate for *E. coli* is about 1 percent per hour (BioNumbers 109924) [36], which equates to 0.00000278 per second; the rate law for peptide concentration can be written as $d[\text{peptide}]/dt = (0.278[\text{mRNA}] - 0.00000278[\text{peptide}]) \text{ uM per second}$. The reactome was modelled as a set of Ordinary Differential Equations (ODEs) where each ODE represented one metabolite concentration [28, 37]. The turnover number of enzyme (Kcat) and Michaelis-Menten constant (Km) were set at 13.7 per second and 1 millimolar respectively; which were the median values estimated by Bar-Even, et al. [38]. The model was written in AdvanceSyn Model Specification [39].

Model Simulation

The constructed model was tested for simulatability using AdvanceSyn Toolkit [39]. Initial concentrations of all mRNA and enzymes were set to 0 mM. Initial concentrations of all metabolites were set to 1 mM except the following which were set to 1000 mM: (i) C00001 (Water), (ii) C00002 (ATP), (iii) C00003 (NAD⁺), (iv) C00004 (NADH), (v) C00005 (NADPH), (vi) C00006 (NADP⁺), (vii) C00007 (Oxygen), (viii) C00008 (ADP), (ix) C00009 (Orthophosphate), (x) C00010 (Coenzyme A), (xi) C00011 (Carbon Dioxide), (xii) C00013 (Diphosphate), (xiii) C00014 (Ammonia), (xiv) C00015 (UDP), (xv) C00016 (FAD), (xvi) C00019 (SAM), (xvii) C00020 (AMP), (xviii) C00021 (S-Adenosyl-L-Homocysteine), (xix) C00022 (Pyruvate), (xx) C00024 (Acetyl-CoA), (xxi) C00025 (L-Glutamate), (xxii) C00029 (UDP-glucose), (xxiii) C00031 (D-Glucose), (xxiv) C00035 (GDP), (xxv) C00037 (Glycine), (xxvi) C00041 (L-Alanine), (xxvii) C00047 (L-Lysine), (xxviii) C00049 (L-Aspartate), (xxix) C00062 (L-Arginine), (xxx) C00064 (L-Glutamine), (xxxi) C00065 (L-Serine), (xxxii) C00078 (L-Tryptophan), (xxxiii) C00079 (L-Phenylalanine), (xxxiv) C00080 (H⁺), (xxxv) C00082 (L-Tyrosine), (xxxvi) C00097 (L-Cysteine), (xxxvii) C00147 (Adenine), (xxxviii) C00148 (L-Proline) and (xxxix) C00183 (L-Valine). The model was simulated using the fourth-order Runge-Kutta method [40, 41] from time zero to 3600 seconds with timestep of 0.1 second and the concentrations of metabolites were bounded between 0 millimolar and 1000 millimolar. The simulation results were sampled every 2 seconds.

Results and Discussion

In this study, we develop four whole cell KMs of *B. subtilis* - one model for each of the four strains (Table 1); namely, 168 (as model bsuLL25), 6051-HGW (as model bshSM25), N33 (as model bsuN33SS25) and FUA2231 (as model bsuGR25). Based on their corresponding GenBank records, the number of protein coding genes ranged from 4243 to 4634. Of which, we are able to identify between 571 to 679 unique EC numbers, which catalyzes between 1300 to 1565 reactions. These reactions used between 1053 to 1681 types of metabolites. The total number of unique EC numbers is 812 (Fig. 2); of which, 506 (62%) are common across all four strains. Notably, *B. subtilis* 168 has the most strain-specific EC numbers ($n = 151$ or 18.6%). This is not surprising as *B. subtilis* 168 is the first *B. subtilis* strain to be sequenced. Hence, likely to be the best annotated [42].

The four resulting models were simulated using AdvanceSyn Toolkit [39]. Our simulation results (Fig. 2) suggest that the model is free from syntax error as the presence of simulation results suggests that the constructed models can be simulated. At the same time, our simulation results show that time course concentrations of six metabolites; namely, water (C00001), coenzyme A (C00010), D-glucose (C00031), L-lysine (C00047), L-arginine (C00062) and L-glutamine (C00064); show various degrees of oscillations, suggesting that the constructed models are able to show time course differences which are characteristics of kinetic models. However, the metabolite concentrations over time cannot be taken at face value as all enzyme kinetics (turnover number and Michaelis-Menten constant) are kept the median levels [33]. Hence, we present four simulatable whole cell KM of *B. subtilis*, which can be a base template for incorporating other cellular and growth processes [43-45] or as a system to examine cellular resource allocations [46-49].

	<i>Bacillus subtilis</i> Strains			
	168	6051-HGW	N33	FUA2231
Number of Protein Coding Genes	4243	4254	4542	4634
Number of Reactions	1565	1369	1305	1300
Number of Unique EC Numbers	679	649	571	650
Number of Metabolites	1554	1681	1388	1053
Model Name	bsuLL25	bshSM25	bsuN33SS25	bsuGR25

Table 1: Statistics of kinetic models.




Figure 1: EC Number Commonalities. Among the 812 unique EC numbers across all 4 strains, 506 (62%) are common across all 4 strains.




Figure 2: Selection of Simulation Results. The time course concentrations of six metabolites; namely, water (C00001), coenzyme A (C00010), D-glucose (C00031), L-lysine (C00047), L-arginine (C00062) and L-glutamine (C00064); are graphed for each of the four KMs. Panel A shows *B. subtilis* 6051-HGW (bshSM25). Panel B shows *B. subtilis* N33 (bsuN33SS25). Panel C shows *B. subtilis* FUA2231 (bsuGR25). Panel D shows *B. subtilis* 168 (bsuLL25).

Conclusion

In this study, we present four whole cell KMs of *B. subtilis* - one KM for each strain of *B. subtilis*; namely, 168 (as model bsuLL25), 6051-HGW (as model bshSM25), N33 (as model bsuN33SS25) and FUA2231 (as model bsuGR25); respectively.

Supplementary Materials

Reaction descriptions and model can be download from the following: (i) <https://bit.ly/bshSM25> (for bshSM25), (ii) <https://bit.ly/bsuN33SS25> (for bsuN33SS25), (iii) <https://bit.ly/bsuGR25> (for bsuGR25) and (iv) <https://bit.ly/bsuLL25> (for bsuLL25).

Note: Sriinithi Maiyappan constructed bshSM25. Shannon SY Sim constructed bsuN33SS25. Geeta Ramesh constructed bsuGR25. Lingxin Low constructed bsuLL25. Hence, Sriinithi Maiyappan, Shannon SY Sim, Geeta Ramesh and Lingxin Low; contributed equally to this work and should be recognized as joint first authors.

Conflict of Interest

The authors have declared no conflict of interest.

Funding

None.

References

- Ruiz N, Silhavy TJ. How *Escherichia coli* became the flagship bacterium of molecular biology. *J Bacteriol.* 2022;204(9):e0023022.
- Errington J, van der Aart LT. Microbe profile: *Bacillus subtilis*: Model organism for cellular development and industrial workhorse. *Microbiology (Reading).* 2020;166(5):425-7.
- Su Y, Liu C, Fang H, Zhang D. *Bacillus subtilis*: A universal cell factory for industry, agriculture, biomaterials and medicine. *Microb Cell Fact.* 2020;19(1):173.
- Stülke J, Gruppen A, Bramkamp M, Pelzer S. *Bacillus subtilis*: A Swiss army knife in science and biotechnology. *J Bacteriol.* 2023;205(5):e00102-23.
- Akinsemolu AA, Onyeaka H, Odion S, Adebajo I. Exploring *Bacillus subtilis*: Ecology, biotechnological applications and future prospects. *J Basic Microbiol.* 2024;64(6):2300614.
- Williams N, Weir TL. Spore-based probiotic *Bacillus subtilis*: current applications in humans and future perspectives. *Fermentation.* 2024;10(2):78.
- Horneck G, Klaus DM, Mancinelli RL. Space microbiology. *Microbiol Mol Biol Rev.* 2010;74(1):121-56.
- Cortês M, Fuchs FM, Commichau FM, Eichenberger P, Schuerger AC, Nicholson WL, et al. *Bacillus subtilis* spore resistance to simulated Mars surface conditions. *Front Microbiol.* 2019;10:333.
- Chen L, Cao C, Wang S, Varcoe JR, Slade RCT, Avignone-Rossa C, et al. Electron communication of *Bacillus subtilis* in harsh environments. *iScience.* 2019;12:260-9.
- Guan Z, Xue D, Abdallah II, Dijkshoorn L, Setroikromo R, Lv G, et al. Metabolic engineering of *Bacillus subtilis* for terpenoid production. *Appl Microbiol Biotechnol.* 2015;99(22):9395-406.
- Miyazawa T, Abe C, Bhaswant M, Ikeda R, Higuchi O, Miyazawa T. Biological functions of compounds from *Bacillus subtilis* and its subspecies, *Bacillus subtilis natto*. *Food Bioeng.* 2022;1(3-4):241-51.
- Xiang M, Kang Q, Zhang D. Advances on systems metabolic engineering of *Bacillus subtilis* as a chassis cell. *Synth Syst Biotechnol.* 2020;5(4):245-51.
- Khanijou JK, Kulyk H, Bergès C, Khoo LW, Ng P, Yeo HC, et al. Metabolomics and modelling approaches for systems metabolic engineering. *Metab Eng Commun.* 2022;15:e00209.
- Gudmundsson S, Nogales J. Recent advances in model-assisted metabolic engineering. *Curr Opin Syst Biol.* 2021;28:100392.
- Richelle A, David B, Demaegd D, Dewerschin M, Kinet R, Morreale A, et al. Towards a widespread adoption of metabolic modeling tools in biopharmaceutical industry: A process systems biology engineering perspective. *NPJ Syst Biol Appl.* 2020;6(1):6.
- Yeo KY, Arivazhagan M, Senthilkumar A, Saisudhanbabu T, Le MA, Wong B, et al. Ab initio whole cell kinetic model of *Yarrowia lipolytica* CLIB122 (yliYKY24). *Medicon Med Sci.* 2025;8(4):1-6.
- Prabhu S, Kosir N, Kothare MV, Rangarajan S. Derivative-free domain-informed data-driven discovery of sparse kinetic models. *Ind Eng Chem Res.* 2025;64(5):2601-15.
- Henry CS, Zinner JF, Cohoon MP, Stevens RL. iBsu1103: A new genome-scale metabolic model of *Bacillus subtilis* based on SEED annotations. *Genome Biol.* 2009;10(6):R69.
- Bi X, Cheng Y, Xu X, Lv X, Liu Y, Li J, et al. etiBsu1209: A comprehensive multiscale metabolic model for *Bacillus subtilis*. *Biotechnol Bioeng.* 2023;120(6):1623-39.
- Wu K, Mao Z, Mao Y, Niu J, Cai J, Yuan Q, et al. ecBSU1: A genome-scale enzyme-constrained model of *Bacillus subtilis* based on the ECmpy workflow. *Microorganisms.* 2023;11(1):178.
- Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, et al. The complete genome sequence of the Gram-positive bacterium *Bacillus subtilis*. *Nature.* 1997;390(6657):249-56.
- Borriss R, Danchin A, Harwood CR, Médigue C, Rocha EPC, Sekowska A, et al. *Bacillus subtilis*, the model Gram-positive bacterium: 20 years of annotation refinement. *Microb Biotechnol.* 2018;11(1):3-17.
- Kabisch J, Thürmer A, Hübel T, Popper L, Daniel R, Schweder T. Characterization and optimization of *Bacillus subtilis* ATCC 6051 as an expression host. *J Biotechnol.* 2013;163(2):97-104.
- Kwan ZJ, Teo W, Lum AK, Ng SM, Ling MH. Ab initio whole cell kinetic model of *Stutzerimonas balearica* DSM 6083 (pbmKZJ23). *Acta Sci Microbiol.* 2024;7(2):28-31.
- Saisudhanbabu T, Yeo KY, Arivazhagan M, Senthilkumar A, Le MA, Wong TB, et al. Ab initio whole cell kinetic model of *Limosilactobacillus fermentum* EFEL6800 (IfeTS24). *EC Clin Med Case Rep.* 2025;8(4):1-4.
- Wong TB, Le MA, Arivazhagan M, Senthilkumar A, Yeo KY, Saisudhanbabu T, et al. Ab initio whole cell kinetic models of *Escherichia coli* BL21 (ebeTBSW25) and MG1655 (ecoMAL25). *Sch Med Sci.* 2025;3(2):1-4.
- Arivazhagan M, Senthilkumar A, Yeo KY, Saisudhanbabu T, Le MA, Wong TB, et al. Ab initio whole cell kinetic model of *Bifidobacterium bifidum* BGN4 (bbfMA24). *Acta Sci Nutr Health.* 2025;9(1):42-5. doi: 10.31080/ASNH.2024.08.1479.

28. Sim BJH, Tan NTF, Ling MHT. Multilevel metabolic modelling using ordinary differential equations. In: Ranganathan S, Cannataro M, Khan AM, editors. Encyclopedia of bioinformatics and computational biology. 2nd Ed. Oxford: Elsevier; 2025;491-8.
29. Müller-Hill B. The lac operon: a short history of a genetic paradigm. Berlin: Springer. 1996.
30. Churchward G, Bremer H, Young R. Transcription in bacteria at different DNA concentrations. J Bacteriol. 1982;150(2):572-81.
31. Gray WJ, Midgley JE. The control of ribonucleic acid synthesis in bacteria. The synthesis and stability of ribonucleic acid in rifampicin-inhibited cultures of *Escherichia coli*. Biochem J. 1971;122(2):161-9.
32. Kubitschek HE. Cell volume increase in *Escherichia coli* after shifts to richer media. J Bacteriol. 1990;172(1):94-101.
33. Hu P, Janga SC, Babu M, Díaz-Mejía JJ, Butland G, Yang W, et al. Global functional atlas of *Escherichia coli* encompassing previously uncharacterized proteins. PLoS Biol. 2009;7(4):e96.
34. So LH, Ghosh A, Zong C, Sepúlveda LA, Segev R, Golding I. General properties of transcriptional time series in *Escherichia coli*. Nat Genet. 2011;43(6):554-60.
35. Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Corrigendum: Global quantification of mammalian gene expression control. Nature. 2013;495(7439):126-7.
36. Maurizi MR. Proteases and protein degradation in *Escherichia coli*. Experientia. 1992;48(2):178-201.
37. Murthy MV, Balan D, Kamarudin NJ, Wang VC, Tan XT, Ramesh A, et al. UniKin1: A universal, non-species-specific whole cell kinetic model. Acta Sci Microbiol. 2020;3(10):4-8.
38. Bar-Even A, Noor E, Savir Y, Liebermeister W, Davidi D, Tawfik DS, et al. The moderately efficient enzyme: Evolutionary and physicochemical trends shaping enzyme parameters. Biochemistry. 2011;50(21):4402-10.
39. Ling MH. AdvanceSyn toolkit: An open source suite for model development and analysis in biological engineering. MOJ Proteomics Bioinform. 2020;9(4):83-6.
40. Yong B. The comparison of fourth order Runge-Kutta and homotopy analysis method for solving three basic epidemic models. J Phys Conf Ser. 2019;1317:012020.
41. Ling MH. COPADS IV: fixed time-step ODE solvers for a system of equations implemented as a set of Python functions. Adv Comput Sci Int J. 2016;5(3):5-11.
42. Moszer I. The complete genome of *Bacillus subtilis*: From sequence annotation to data management and analysis. FEBS Lett. 1998;430(1-2):28-36.
43. Ahn-Horst TA, Mille LS, Sun G, Morrison JH, Covert MW. An expanded whole-cell model of *E. coli* links cellular physiology with mechanisms of growth rate control. NPJ Syst Biol Appl. 2022;8(1):30.
44. Chagas MS, Trindade Dos Santos M, Argollo de Menezes M, da Silva FAB. Boolean model of the gene regulatory network of *Pseudomonas aeruginosa* CCBH4851. Front Microbiol. 2023;14:1274740.
45. Hao T, Song Z, Zhang M, Zhang L, Yang J, Li J, et al. Reconstruction of metabolic-protein interaction integrated network of *Eriocheir sinensis* and analysis of ecdysone synthesis. Genes (Basel). 2024;15(4):410.
46. Thornburg ZR, Bianchi DM, Brier TA, Gilbert BR, Earnest TM, Melo MCR, et al. Fundamental behaviors emerge from simulations of a living minimal cell. Cell. 2022;185(2):345-60.e28.
47. Bianchi DM, Pelletier JF, Hutchison CA, Glass JI, Luthey-Schulten Z. Toward the complete functional characterization of a minimal bacterial proteome. J Phys Chem B. 2022;126(36):6820-34.
48. Sun G, DeFelice MM, Gillies TE, Ahn-Horst TA, Andrews CJ, Krummenacker M, et al. Cross-evaluation of *E. coli*'s operon structures via a whole-cell model suggests alternative cellular benefits for low- versus high-expressing operons. Cell Syst. 2024;15(3):227-45.e7.
49. Choi H, Covert MW. Whole-cell modeling of *E. coli* confirms that *in-vitro* tRNA aminoacylation measurements are insufficient to support cell growth and predicts a positive feedback mechanism regulating arginine biosynthesis. Nucleic Acids Res. 2023;51(12):5911-30.

Publish your work in this journal

Journal of Clinical Immunology & Microbiology is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries. All aspects of immunology or microbiology research, health maintenance, preventative measures and disease treatment interventions are addressed within the journal. Immunologist or Microbiologist and other researchers are invited to submit their work in the journal. The manuscript submission system is online and journal follows a fair peer-review practices.

Submit your manuscript here: <https://athnaeumpub.com/submit-manuscript/>